TARRYTOWN, N.Y., Jan. 29, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Karen Ferrante, M.D., a healthcare industry leader with more than two decades of experience in the areas of oncology and clinical research and development, has been elected to its Board of Directors. Most recently Dr. Ferrante held the positions of Chief Medical Officer and was a Head of R & D at Millennium, The Takeda Oncology Company, and Oncology Therapeutic Area Head at Takeda Pharmaceutical Company.
"Karen's extensive experience in oncology and clinical development supports our strategic focus in late stage oncology and complements the areas of expertise of our current Board members," said Mark R. Baker, Chief Executive Officer. "Karen's election rounds out this talented and dedicated group upon whom we rely to guide us toward our goal of becoming a pre-eminent oncology company."
"The appointment of Karen to our Board is further evidence of our commitment to building our presence in the oncology space; to improving the lives of the patients and families touched by this disease and, in doing so, create value for our shareholders," said Peter Crowley, Chairman of the Board of Progenics.Dr. Ferrante held senior positions at Millennium Pharmaceuticals and its parent company, Takeda Pharmaceuticals, most recently as Oncology Therapeutic Area and Cambridge USA Site Head. She held positions of increasing responsibility at Pfizer Global Research & Development, culminating as Vice President, Oncology Development. Dr. Ferrante began her career in the pharmaceutical industry as Associate Director of Clinical Oncology at Bristol-Myers Squibb Company. For more than a decade prior, she was at the New England Deaconess Hospital in Boston (Beth Israel Deaconess), where she completed her internship and residency in internal medicine followed by her fellowship in hematology and oncology. While at the Beth Israel Deaconess Hospital, she served as Clinical Instructor and Clinical Fellow in Medicine at the Harvard Medical School.